85307
document
Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline : a prospective , randomized trial . Elevated levels of tumor necrosis factor alpha ( TNF-alpha ) have been reported to correlate with the development of transplant-related complications after bone marrow transplantation ( BMT ) . In a recent phase I-II trial , oral administration of pentoxifylline ( PTX ) , a xanthine derivative capable of downregulating TNF-alpha production in vitro , was reported to reduce morbidity and mortality in patients undergoing BMT . We conducted a prospective randomized trial of PTX therapy among 140 patients undergoing either allogeneic ( n = 51 ) or autologous BMT ( n = 89 ) . Patients were randomized to receive ( n = 70 ) or not receive ( n = 70 ) oral PTX , 1,600 mg/d in four divided doses from day -8 until day + 100 post-BMT . The incidence of mucositis requiring morphine sulfate ( MSO4 ) was similar in both groups ( 42.9 % ) , with the mean number of days with MSO4 being 7.8 ( SD = 3.4 ) in the PTX group versus 8.2 ( SD = 3.4 ) in the control group ( NS ) . The incidence of renal insufficiency was not affected by PTX administration ( 15.7 % in the PTX group v 21.4 % in the control group [ NS ] ) and the highest serum creatinine value during the first 100 days post-BMT was 119 mumol/L ( SD = 82.4 ) in the PTX group versus 103.9 mumol/L ( SD = 57 ) in the control group ( NS ) . The incidence of grade > or = 2 graft-versus-host disease was similar in each group ( 11/25 [ 44 % ] in the PTX group v 12/26 [ 46 % ] in the control group ) . No significant difference was observed in hematologic toxicity , transfusion requirements , duration of fever , and hepatic toxicity between the treatment groups . In conclusion , our study failed to show a prophylactic effect of PTX in transplant-related toxicities after BMT . On the basis of these findings , we can not recommend that PTX be part of early mortality and morbidity prevention programs after BMT .
85308
Intervention_Pharmacological
pentoxifylline
85309
Intervention_Pharmacological
pentoxifylline ( PTX )
85310
Intervention_Pharmacological
PTX
85311
Intervention_Pharmacological
PTX
85312
Intervention_Pharmacological
PTX
85313
Intervention_Pharmacological
PTX
85314
Intervention_Pharmacological
PTX
85315
Outcome_Physical
incidence of mucositis requiring morphine sulfate ( MSO4 )
85316
Outcome_Physical
incidence of renal insufficiency
85317
Outcome_Physical
serum creatinine value
85318
Outcome_Physical
incidence of grade > or = 2 graft-versus-host disease
85319
Outcome_Physical
hematologic toxicity
85320
Outcome_Physical
transfusion requirements
85321
Outcome_Physical
duration of fever
85322
Outcome_Physical
hepatic toxicity
85323
Participant_Condition
after bone marrow transplantation by pentoxifylline
85324
Participant_Condition
bone marrow transplantation ( BMT ) .
85325
Participant_Condition
BMT
85326
Participant_Sample-size
140
85327
Participant_Sample-size
51
85328
Participant_Condition
BMT
85329
Participant_Sample-size
89
85330
Participant_Condition
BMT